CONSUMER ORDERS CLINICAL STORE REGISTER PORTAL About Science GARS® restoreGen® Diagnostics MyGenx® U.S. Providers Clinical Store GARS™ for Addiction Prevention Strategiesoddicte Prevention is the first step in lowering addiction statistics. Research has shown 1/3 of the U.S. population carries genetic mutations that result in a predisposition to certain addictive behaviors. A person’s genetics only make up 50% of addiction predisposition; environmental factors make up the other 50%. If a person gets tested and finds out they have a high predisposition to nicotine, it does NOT mean they are going to become addicted to smoking. If that person never smokes a cigarette or is not exposed to smoking environments, then that addictive behavior is not triggered. It is very important for people to understand their addictive predispositions so they can manage themselves better and minimize exposure to these potentially "at risk" environments. The same holds true for prescription opioids. GARS® brings a multitude of benefits to both patients and healthcare providers. The U.S. is facing an opioid crisis, leading to a bigger addiction problem. Opioids are just one of the drug classes being abused. The classes of prescription drugs most commonly abused are: opioid pain relievers, such as Vicodin® or Oxycontin®; stimulants for treating Attention Deficit Hyperactivity Disorder (ADHD), such as Adderall®, Concerta®, or Ritalin®; and central nervous system (CNS) depressants for relieving anxiety, such as Valium® or Xanax®. Healthcare providers do the best they can with the information they have to determine how to care for a patient, but the potential for abuse and addiction, along with addiction tendencies are not always easily determined or observed in patients, until there’s a problem. A PROPHYLACTIC APPROACH GARS® can provide insight to a patient’s genetic predisposition to addictive behaviors and offers health care providers the opportunity to provide a personalized approach to patient care. GARS® is a powerful tool for healthcare providers to use when they want to prescribe a narcotic to a patient. GARS® will identify whether or not the patient has a high predisposition to opioid addictive behavior. This will guide the physician to determine the best way to manage the patient’s treatment/medications. If a patient shows to have a high predisposition to opioids, then a provider might want to start with a non-opioid medication. If there are no other alternatives and the patient must be prescribed an opioid, then the test should alert the physician that this patient needs to be prescribed a lower grade opioid, for a shorter amount of time, with more monitoring, to help prevent addiction. Thanks to the in-depth research of Dr. Blum and advances in technology, GARS® reveals the genetics behind substance and non-substance abuse behaviors. Addiction can be avoided, if you have the right information. What does your DNA say about you? Our goal is to provide this powerful science and technology to improve behavioral predictive medicine and management for people everywhere. We put the power of understanding more about who YOU are into your hands! CONTACT San Antonio,TX Phone: 844-800-2334 LEGAL Privacy Policy Terms & Conditions GARS® Test References PROVIDER PORTAL GET IN TOUCH Name: Email: Message: © 2020 All rights reserved Geneus